CRISPR gene editing

Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September

Retrieved on:

Tuesday, September 7, 2021

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the XIXth International Symposium on Retinal Degeneration (RD2021) being held in Nashville, Tenn., and virtually September 28 – October 2, 2021. EDIT-101 is under development for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.

Key Points:

EDIT-101 is under development for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.
We look forward to sharing our Companys first clinical data at RD2021 and our progress towards developing a transformative gene editing medicine for people living with CEP290-related retinal degeneration.
I would like to thank all of the patients who have and will participate in this landmark gene editing medicine clinical trial.
The presentation will include patient safety assessments and a preliminary analysis of secondary endpoints relating to signals of gene editing and clinical benefit.

DGAP-News: BRAIN Biotech AG: Sartorius and BRAIN jointly researching and adapting novel CRISPR Cas-nucleases

Retrieved on:

Wednesday, July 28, 2021

Branches of biology, Biology, Life sciences, Genetic engineering, Biotechnology, Genome editing, Emerging technologies, Immune system, CRISPR, Sartorius, CRISPR gene editing

Goettingen / Zwingenberg (Germany), July 28, 2021

Key Points:

Goettingen / Zwingenberg (Germany), July 28, 2021
The life science group Sartorius and BRAIN Biotech AG are jointly researching and adapting novel CRISPR-Cas genome editing nucleases for specific applications in the field of life sciences.
Within the research project Sartorius is testing the novel CRISPR-Cas genome editing nucleases on a range of cell lines.
To this end, Sartorius and BRAIN are collaborating on a promising early-stage genome editing technology portfolio.
Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group.

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement

Retrieved on:

Tuesday, July 27, 2021

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, today announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics CRISPR/Cas9 patent portfolio.

Key Points:

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, today announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics CRISPR/Cas9 patent portfolio.
We are proud to add Japan SLC to our growing list of partners in Japan applying CRISPR/Cas9 technology to its service offerings, said Eric Rhodes, CEO of ERS Genomics.
Japan SLCs animal production and supply are of high quality, and we are very pleased that it has chosen to license CRISPR/Cas9 technology through ERS Genomics.
We are very excited to sign this licensing agreement with ERS Genomics which will enable us to produce CRISPR-edited mouse and rat models.

DGAP-News: BRAIN Biotech AG: Novel Genome Editing Tool: Filing of International Patent Application

Retrieved on:

Wednesday, July 21, 2021

Branches of biology, Genetic engineering, Genome editing, Biology, Life sciences, Immune system, Cas9, CRISPR gene editing, Protospacer adjacent motif

DGAP-News: BRAIN Biotech AG

/ Key word(s): Patent

BRAIN Biotech AG: Novel Genome Editing Tool: Filing of International Patent Application

21.07.2021 / 07:30

The issuer is solely responsible for the content of this announcement.

Key Points:

Positive data evaluation from recently conducted experiments has increased confidence of BRAIN Biotech AG's management in the valuable IP position of its Non-Cas9 genome editing nuclease, the BRAIN Engineered CAS (BEC).
In order to secure a broad intellectual property position on a global scale BRAIN has now advanced in the international patent filing process under the Patent Cooperation Treaty (PCT) formalities.
BRAIN is striving for an extended patent family around its BEC genome editing tool to further progress on the IP position already within the course of this year.
Auspicious genome editing in plant cells has been achieved and is in the process to be validated.

DGAP-News: BRAIN Biotech AG: Additional CRISPR Genome Editing Nucleases Identified

Retrieved on:

Friday, July 16, 2021

Branches of biology, Biology, Life sciences, Genetic engineering, Genome editing, Biotechnology, Emerging technologies, Molecular biology, CRISPR, CRISPR gene editing

BRAIN Biotech AG has identified around 2,000 so far untapped additional Class 2 CRISPR Nucleases using metagenomics sequencing which could be deployed for genome editing.

Key Points:

BRAIN Biotech AG has identified around 2,000 so far untapped additional Class 2 CRISPR Nucleases using metagenomics sequencing which could be deployed for genome editing.
Dr. Paul Scholz, heading the Cas nuclease discovery program at BRAIN Biotech AG states: "The now identified Class 2 CRISPR Nucleases will give us a strong basis to develop a broader diversity of genome editing tools.
We are very pleased that BRAIN can now make a strong contribution to the evolution of genome editing."
Dr. Michael Krohn, Head R&D at BRAIN Biotech AG says: "We are expanding our footprint in genome editing.

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement

Retrieved on:

Thursday, July 1, 2021

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics CRISPR/Cas9 patent portfolio.

Key Points:

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics CRISPR/Cas9 patent portfolio.
The license from ERS Genomics will allow Nippon Gene to develop, manufacture, and sell research reagents using CRISPR/Cas9 technology.
Eric Rhodes, CEO of ERS Genomics, said: Our portfolio of Japanese companies taking a license to the CRISPR/Cas9 technology is growing rapidly, and we are very pleased to be working with Nippon Gene.
The license from ERS Genomics, granting us access to the foundational CRISPR/Cas9 patents, will enable us to supply a wide range of research reagents in the field of gene editing.

As FDA considers Cutting Nicotine in Cigarettes, Demeetra AgBio Announces It Can Produce Harm-Reduced Tobacco Products Through Gene Editing

Retrieved on:

Wednesday, June 16, 2021

Branches of biology, Biology, Genetic engineering, Genome editing, Immune system, Biotechnology, Nicotinic agonists, Cas9, CRISPR, Tobacco, Nicotine, CRISPR gene editing

Notably, Nobel Prize-winning gene editing platform CRISPR/Cas9 cannot be licensed to create tobacco products for human consumption.

Key Points:

Notably, Nobel Prize-winning gene editing platform CRISPR/Cas9 cannot be licensed to create tobacco products for human consumption.
"We are just scratching the surface on what our gene editing platforms can unlock", said Jack Crawford, Chief Executive Officer
What is Cas-CLOVER?
Demeetra's gene editing technology can resolve several key problems, including reducing carcinogens and offering a biological process for the stepwise reduction of nicotine in cigarettes.
Demeetra AgBio is open for licensing and services to modify any tobacco strain, variety, or other crop with itsprecise gene editing technology.

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia

Retrieved on:

Tuesday, June 15, 2021

Branches of biology, Biology, Life sciences, Biotechnology, Genetic engineering, Applied genetics, Biological engineering, Emerging technologies, CRISPR Therapeutics, Adeno-associated virus, CRISPR, CRISPR gene editing

CRISPR Therapeutics and Capsida will each have the option to co-develop and co-commercialize the program that the other company leads.

Key Points:

CRISPR Therapeutics and Capsida will each have the option to co-develop and co-commercialize the program that the other company leads.
Following such option, the companies would equally share all research, development and commercialization costs and profits worldwide related to the collaboration product.
The combination of Capsidas AAV engineering platform and CRISPR Therapeutics gene-editing platform has the potential to enable transformative gene-edited therapies for patients with neurological diseases, said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics.
Capsida Biotherapeutics Inc. is developing tissue-targeted gene therapies using its biologically driven, high-throughput adeno-associated virus (AAV) engineering and proprietary cargo development platform.

ERS Genomics: Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third

Retrieved on:

Tuesday, June 1, 2021

In addition, the JPO has allowed a third CVC patent (JP2019-210828), which covers a chimeric version of the Cas9 protein.

Key Points:

In addition, the JPO has allowed a third CVC patent (JP2019-210828), which covers a chimeric version of the Cas9 protein.
This patent covers compositions and uses of a chimeric version of the Cas9 protein in cellular and non-cellular settings and will represent the third Japanese patent granted to the group.
Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: The JPO actions reinforce the broad and fundamental nature of our CRISPR patent portfolio, both in Japan and worldwide.
This also validates the decision our licensees have made to work with ERS to enable their commercialization efforts involving CRISPR/Cas9.

Argentine companies Gensus and Bioheuris to develop non-GMO herbicide resistant cotton using gene editing

Retrieved on:

Tuesday, May 11, 2021

Branches of biology, Biology, Life sciences, Biotechnology, Genetic engineering, Emerging technologies, Molecular biology, Pesticides, Cotton, Genetically modified organism, Herbicide, CRISPR gene editing

b'ROSARIO, Argentina, May 11, 2021 /PRNewswire/ -- Bioheuris , an agbiotech startup using synthetic biology and gene editing to fight weeds, and Gensus , the Argentine company that produces and markets certified cotton seeds, today announced a partnership to develop herbicide resistance in this crop using CRISPR gene editing.\nHerbicide-resistant (HR) GMO cotton expressing genes from other species are already available for farmers in several countries.

Key Points:

b'ROSARIO, Argentina, May 11, 2021 /PRNewswire/ -- Bioheuris , an agbiotech startup using synthetic biology and gene editing to fight weeds, and Gensus , the Argentine company that produces and markets certified cotton seeds, today announced a partnership to develop herbicide resistance in this crop using CRISPR gene editing.\nHerbicide-resistant (HR) GMO cotton expressing genes from other species are already available for farmers in several countries.
"New solutions and greater diversity of tools are key to empower cotton farmers and for the future of the cotton industry.
More than 20 troublesome weeds can reduce cotton yield by more than 50% and contaminate cotton lint, reducing quality.\nHerbicide use in cotton is restricted to specific time windows.
Powered by synthetic biology and gene editing platforms in Argentina and the United States, Bioheuris accelerates plant breeding to evolve crops faster than weeds.